Hansa Biopharma GAAP EPS of -SEK 2.53, revenue of SEK 49.1M

6 hours ago 1

Hansa Biopharma press release (OTC:HNSBF): Q2 GAAP EPS of -SEK 2.53.
Revenue of SEK 49.1M (+43.1% Y/Y).
As compared to prior year Q2 IDEFIRIX product sales increased 76%.
In Q2 2025, the company delivered SEK 47.8 M in IDEFIRIX sales reflecting an increase of 76% as compared to previous year (SEK 27.2 M) for the same time period.

Recommended For You